Prescribing Information for Canadian Physicians
Bezalip® SR, a prescription medication is a modified-release tablet that contains the active ingredient bezafibrate, which is a type of medicine known as a fibrate. Bezalip® SR is indicated as an adjunct to diet and other therapeutic measures for mixed hyperlipidemia. Hyperlipidemia is defined as the elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein (HDL) level that contributes to the development of atherosclerosis. Causes may be primary (genetic) or secondary. Diagnosis is by measuring plasma levels of total cholesterol, TGs, and individual lipoproteins. Treatment is dietary changes, exercise, and may include lipid-lowering drugs.
High levels of cholesterol and triglycerides have been shown to increase the risk of atherosclerosis, angina and heart attacks (coronary heart disease).It is important to continue to follow a cholesterol-lowering diet and exercise regime while taking bezafibrate.
Bezalip® SR tablets are modified-release tablets. They are designed to release the bezafibrate slowly and continuously over the day, so that only one dose needs to be taken each day. The tablets must be swallowed whole to avoid damaging the modified-release action.
For information on side effects, warnings, precautions, interactions and proper use of this medicine, please refer to the Consumer Information
section or consult with your doctor or pharmacist.
About Metabolic Syndrome
Canadian Heart and Stroke Foundation
American Heart Association